Compare Bristol-Myers Squibb Co (BMY) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Fiverr International Ltd — how do they compare? Bristol-Myers Squibb Co trades at $64.12 (market cap $130.12B), while Fiverr International Ltd trades at $8.76 (market cap $311.33M). The key difference: Bristol-Myers Squibb Co is far larger — about 417.9× Fiverr International Ltd's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| BMY | FVRR | |
|---|---|---|
Market Cap | $130.12B | $311.33M |
Sector | Health | Industrials |
52-Week High | $65.89 | $26.67 |
52-Week Low | $42.60 | $8.66 |
Enterprise Value | $164.11B | $63.72M |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Fiverr International (FVRR) trades at $8.66, down 4.73% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation ratios with a P/E of 10.8 and P/S of 0.77, but faces headwinds from AI disruption compressing demand for freelance services. Revenue declined to $97.8 million in Q2 2026 (MarketBeat, July 29, 2026), contributing to a lowered full-year outlook.
The investment outlook is cautious. While valuations appear cheap and the company maintains a strong gross margin of 82%, significant risks from competitive AI technologies and recent execution challenges temper near-term optimism. Analyst consensus leans Hold with a $10.70 price target, suggesting limited upside from current levels amid transitional pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
